On November 17, DUALITYBIO-B fell 4.01% in Regular Trading to HK$93.5, with turnover of HK$51.108 million.
The clearest disclosed catalyst is that the company announced another share buyback, but the stock remained under pressure as the market continued to digest the earlier clinical-data-related setback, leaving near-term support limited.
Background disclosures show DUALITYBIO-B said on November 16 that it repurchased 45,400 shares on the Hong Kong Stock Exchange at HK$96.00 to HK$98.95 per share, for about HK$4.43 million, with the repurchased shares to be held in treasury. This followed multiple buybacks earlier in November and repeated on-market purchases by Chairman Zhu Zhongyuan since late October, including a November 10 purchase at HK$107.276 per share. Even so, the latest price has fallen below both the recent buyback range and the chairman's accumulation range, indicating confidence signals from management have so far had limited effect on short-term trading.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments